Investigational drug · Phase 2
Zelquistinel
Also called: GATE-251
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Major Depressive Disorder.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
6
Any phase or sponsor naming "Zelquistinel"
First trial start
2025
Feb 3, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Zelquistinel", any sponsor or status.
Conditions studied
As listed on its trial records.
- Major Depressive Disorder
Approved drugs for the same conditions: Depression (major depressive disorder) · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "Zelquistinel" as an intervention, largest first.
- Zelquistinel in the Treatment of Major Depressive DisorderPivotal-lookingCompleted
Syndeio Biosciences, IncIndustry
NCT03586427 · 251 participants · Start Jun 13, 2018 · Primary completion Jul 22, 2019
Drug: AGN-241751; Placebo · For: Depressive Disorder, Major
Sites: Fayetteville, Arkansas; Cerritos, California; Encino, California · 25 sites in all
- Zelquistinel in the Treatment of Adults With Major Depressive DisorderPivotal-lookingCompleted
Syndeio Biosciences, IncIndustry
NCT03726658 · 226 participants · Start Nov 8, 2018 · Primary completion Oct 23, 2019
Drug: AGN-241751; Placebo · For: Major Depressive Disorder
Sites: Phoenix, Arizona; Garden Grove, California; Atlanta, Georgia · 5 sites in all
- A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive DisorderPivotal-lookingRecruiting
Syndeio Biosciences, IncIndustry
NCT07115329 · 164 participants (planned) · Start Jan 5, 2026 · Primary completion Mar 30, 2028
Drug: Zelquistinel · For: Major Depressive Disorder
Sites: Phoenix, Arizona; Tucson, Arizona; Montclair, California · 32 sites in all
- Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive DisorderPivotal-lookingRecruiting
Syndeio Biosciences, IncIndustry
NCT06547489 · 164 participants (planned) · Start Feb 3, 2025 · Primary completion Sep 2027
Drug: Zelquistinel · For: Major Depressive Disorder
Sites: Birmingham, Alabama; Huntsville, Alabama; Encino, California · 34 sites in all
Syndeio Biosciences, IncIndustry
NCT04981561 · 68 participants · Start Dec 9, 2016 · Primary completion Dec 21, 2017
Drug: zelquistinel; Placebo · For: Major Depressive Disorder
- Pharmacokinetics of Zelquistinel in Fasted or Fed StateActive, not recruiting
Syndeio Biosciences, IncIndustry
NCT07099989 · 32 participants (planned) · Start Jul 24, 2025 · Primary completion Feb 5, 2026
Drug: Zelquistinel 3 mg; Zelquistinel 10 mg · For: Healthy Volunteers in Fed and Fasted State
Sites: Overland Park, Kansas
Newest research
PubMed records naming it or its code names, newest first.
- Next-Generation Pharmacotherapies for Unipolar Mood Disorders: A Leading Article on Phase II/III Drug Development Across Diverse Mechanisms.
King A, Hardy M, Rhee TG, et al. · CNS Drugs 2026
- New advances in small molecule drugs targeting NMDA receptors.
Zeng Y, Qu ZY, Zhu QW, et al. · Acta Pharmacol Sin 2026
- All roads lead to glutamate: NMDA and AMPA receptors as targets for rapid-acting antidepressants.
Freudenberg F, Reif-Leonhard C, Dawson GR, et al. · Pharmacol Res 2025
- Demystifying the Antidepressant Mechanism of Action of Stinels, a Novel Class of Neuroplastogens: Positive Allosteric Modulators of the NMDA Receptor.
Donello JE, McIntyre RS, Pickel DB, et al. · Pharmaceuticals (Basel) 2025
- Zelquistinel acts at an extracellular binding domain to modulate intracellular calcium inactivation of N-methyl-d-aspartate receptors.
Zhang XL, Li YX, Berglund N, et al. · Neuropharmacology 2024
- The NMDA receptor modulator zelquistinel durably relieves behavioral deficits in three mouse models of autism spectrum disorder.
Fonteneau M, Brugoux A, Jaccaz D, et al. · Neuropharmacology 2024
Also in development for Major Depressive Disorder
- BrenipatideLY3537031Phase 313 trials
Eli Lilly · Alcohol Use Disorder, Irritable Bowel Syndrome, Depressive Disorder, Major
- AzetukalnerXEN1101Phase 39 trials
Xenon Pharmaceuticals Inc. · Focal Onset Seizures, Major Depressive Disorder, Bipolar Disorder
- SEP-363856UlotarontPhase 37 trials
Otsuka · Generalized Anxiety Disorder, Schizophrenia, Major Depressive Disorder
- BHV-7000Phase 36 trials
Biohaven Therapeutics Ltd. · Focal Epilepsy, Major Depressive Disorder, Bipolar Disorder
- NBI-1065845TAK-653, OsavampatorPhase 35 trials
Neurocrine Biosciences · Major Depressive Disorder
- CYM-53093Navacaprant, NMRA-335140Phase 34 trials
Neumora Therapeutics, Inc. · Major Depressive Disorder, Major Depressive Episode Associated With Bipolar II Disorder
- DT120MM120, lysergide tartratePhase 34 trials
Definium Therapeutics US, Inc. · Generalized Anxiety Disorder, Major Depressive Disorder
- PsilocybinCOMP360Phase 34 trials
COMPASS Pathways · Treatment Resistant Depression, Major Depressive Disorder, Anorexia Nervosa
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.